In a first for wearables, Glasgow, UK-based Novosound is demonstrating ultrasound blood pressure monitoring at CES 2025 in Las Vegas this week (January 7-10).

The company reports it has been able to achieve accuracy levels comparable to conventional electronic cuff devices via the miniaturization of its technology in wearable devices.

Built on Novosound’s Slanj platform and utilising thin-film ultrasound technology, the company has already demonstrated the system in real-world settings including public spaces.

 “Our technology has the potential to bridge the gap between individuals, the wearables industry and healthcare providers,” says Novosound CEO and co-founder Dave Hughes. “Having a product that continuously tracks blood pressure in real-time is considered by many to be the holy grail when it comes to health and we are proving that ultrasound provides the answer.

“The ability to monitor on a 24/7 basis combined with the related veracity of the data is something that takes things to the next level and will be transformative in healthcare, enabling early detection of potential health issues and more effective management of hypertension.”

According to the World Health Organisation, over a billion adults aged between 30-79 have high blood pressure or hypertension worldwide, with around one in two people unaware that they have the condition.

Blood pressure is displayed as two numbers. The first (systolic) number represents the pressure in the blood vessels when the heart contracts or beats, while the second (diastolic) represents the pressure in the vessels when the heart rests between beats.

Historically, hypertension is diagnosed if, when it is measured in two different days, the systolic blood pressure readings on both days are greater than 140 mmHG and/or the diastolic blood pressure readings on both days are less than 90 mmHG.

www.novosound.net